ABOUT US

INVESTORS

Kleiner Perkins Caufield & Byers

Kleiner Perkins Caufield & Byers (KPCB) is an active venture capital partnership headquartered in the San Francisco Bay Area with a large capital base for investment.  Since 1972, KPCB has invested in over 400 technology companies which have accrued market valuations exceeding $164 billion, achieved combined revenues of over $81 billion, and created over 279,000 jobs.  In this process, KPCB has been privileged to work with some of America's most outstanding entrepreneurs, Chief Executive Officers, and management teams.

TPG Ventures

Texas Pacific Group (TPG) is a private equity investment firm founded by David Bonderman, James G. Coulter, and William S. Price, III in 1993.  The principals of TPG, with affiliated partnerships, have aggregate committed capital of more than $5 billion.  TPG’s diverse holdings include Oxford Health Plans, Magellan Health Services, Paradyne Networks, Ducati Motor, J. Crew Group, Landis & Gyr Communications, and WR Hambrecht + Co.  Founded in 2001, Texas Pacific Group Ventures has a total of $500M devoted to investments in information technology and the life sciences in the United States.

BOARD OF DIRECTORS

Risa Stack, Ph.D.

Dr. Stack joined Kleiner Perkins Caufield & Byers in 2003.  Dr. Stack specializes in the development of life science companies.  She was the founding CEO and is currently a board member of several companies including CardioDx, Nodality, and an incubation in the personalized medicine area.  She is a board observer at Codon Devices, XDx, Orexigen (OREX), Tethys, and Pacific Biosciences.  Prior to joining KPCB, Dr. Stack was a Principal at J.P. Morgan Partners in the life science practice for 6 years.  While at J.P. Morgan Partners she sponsored a series of investments including Acurian, AlgoRx (now Anesiva), Connetics, Diatide, Ilex Oncology, Illumina, Praecis Pharmaceuticals and Triangle Pharmaceuticals.

Prior to working in the venture capital industry, Dr. Stack worked as a Derivative Specialist on the Chicago Board of Trade where she traded futures and options on government securities.  As an intern at ARCH Development Corporation she participated in the development of several companies based on the research of University of Chicago scientists.  At Abbott Laboratories, she worked to develop a new Hepatitis C assay system and researched new procedures for evaluating patient samples for HIV and Hepatitis B.  Dr. Stack received her B.S. in Genetics and Development with distinction from the University of Illinois and her Ph.D. in Immunology from the University of Chicago.  She was also a member of the second class of Kauffman Fellows.  Dr. Stack was named as one of the 100 Most Influential Women in Business by the San Francisco Business Times in 2004.

Fred Cohen, M.D., Ph.D.

Dr. Cohen is a partner at TPG, where he initiated their investment efforts in the life sciences forming TPG Biotechnology.  He also retains a position as a Professor of Cellular and Molecular Pharmacology at the University of California, San Francisco.  He also serves as a member of the boards of GenomicHealth, XDx, Kemia, CardioDx, Anaborex, Quintiles Transnational, Five Prime Therapeutics, and Matrix Laboratories.  He received his M.D. from Stanford, his D.Phil. in Molecular Biophysics from Oxford as a Rhodes Scholar and his Bachelor’s degree from Yale University in Molecular Biophysics and Biochemistry.  Dr. Cohen has been a member of the faculty of UCSF since 1986 and is best known for his work on protein structure and the conformational basis of prion disease. He is a member of the Institute of Medicine of the National Academy of Sciences.

Garry P. Nolan, Ph.D.

Dr. Nolan received his Ph.D from the Department of Genetics at Stanford at the Herzenberg laboratory, and his B.S. in Biology from Cornell University.  He is the author of over 120 peer-reviewed papers and holds numerous issued patents.  He is the recipient of several prestigious awards, and was recently honored as one of the top 25 inventors at Stanford University.  He was a Hume Faculty Scholar (1993-98), Trustee of the Leukemia Society of America (1995-98), Burroughs Welcome Fund New Investigator Awardee (1996-2000), HHMI Junior Faculty Scholar Awardee, Leukemia and Lymphoma Society Stohlman Scholar (2000), among others.  He is the co-founder of 3 companies, including publicly traded RIGEL (NASDAQ:RIGL).

David R. Parkinson, M.D.

David R. Parkinson, M.D. joined Nodality in September of 2007.  Previously, he served as senior vice president, Oncology Research and Development since joining Biogen Idec in March 2006, where he oversaw all oncology discovery research efforts and the development of the oncology pipeline.

Dr. Parkinson joined Biogen Idec from Amgen where he was Vice President, Oncology Development.  Previously, he held several senior oncology positions at Novartis.  During his tenure at both companies, Dr. Parkinson was responsible for clinical development activities leading to a series of successful global drug registrations for important cancer therapeutics, including Gleevec, Femara, Zometa, Kepivance, and Vectibix, among others.

Dr. Parkinson worked at the National Cancer Institute from 1990 to 1997, serving as Chief of the Investigational Drug Branch, then as Acting Associate Director of the Cancer Therapy Evaluation Program before leaving for Novartis.  He had previously also held academic positions at the M.D. Anderson Cancer Center, University of Texas and New England Medical Center, Tufts University School of Medicine.

He received his M.D. from the University of Toronto Faculty of Medicine in 1977, with Internal medicine and Hematology/Oncology training in Montreal at McGill University and then in Boston at New England Medical Center.  Currently, Dr. Parkinson serves on the National Cancer Policy Forum of the Institute of Medicine.  He is a past Chairman of the FDA Biologics Advisory Committee and is a recipient of the FDA’s Cody Medal.  He currently is a member of the FDA’s Science Board.  He was recently elected to the Board for Directors of the American Association of Cancer Research, and continues to serve as Chairperson of the AACR Finance Committee.

MANAGEMENT TEAM

David R. Parkinson, M.D.

David C. Spellmeyer, Ph.D.

Dr. Spellmeyer joined Nodality in September of 2006.  Prior to Nodality, he held positions as a research staff member in the IBM Almaden Services Research group, as chief scientific officer and vice president of drug discovery at Signature BioSciences, as executive director at DuPont Pharmaceuticals, as vice president at CombiChem, and a principal scientist at Chiron.  Dr. Spellmeyer received his Ph.D. in 1987 from UCLA, and completed his post-doctoral work in pharmaceutical chemistry at UCSF.  He continues his interaction with the UCSF research groups through his adjunct assistant professorship.  He has authored more than 35 scientific publications and two modeling packages, and frequently makes presentations at scientific seminars.

Wendy J. Fantl, Ph.D.

Dr. Fantl joined Nodality in February of 2007. Previously, she served as Vice President of translational medicine at Quark Pharmaceuticals. Between 1994 and 2006, she held several positions at Chiron Corporation, including Director of Cancer Biology.  Dr. Fantl received her Ph.D. in 1985 from Rockefeller University, completed her post-doctoral work in the laboratory of Dr. Lewis “Rusty” Williams at UCSF before being appointed Adjunct Assistant Professor in the Cardiovascular Research Institute, Department of Medicine at UCSF.  Dr. Fantl’s expertise in signal transduction and its application to drug development and cancer research has resulted in 9 patents filed and 31 publications in journals including Nature and Cell, and has provided the basis for the selection of several therapeutic targets in drug discovery and development.

Thomas P. O’Neil

Mr. O’Neil joined Nodality in March of 2007.  From 1999 to 2007, he held several finance positions at Monogram Biosciences, Inc. most recently as Director of Financial Planning & Analysis.  Prior to Monogram, Mr. O’Neil held finance, operations, and business development positions with Autodesk, Nellcor/Tyco Healthcare, Miller Freeman, and the ASM Group.  He holds a BA from Pomona College and an MBA from Anderson Graduate School of Management at UCLA.